PURPOSE: The efficacy of curative low-dose-rate (LDR) brachytherapy for recurrent and/or residual cancer following radical operation or irradiation and posttreatment quality of life (QoL) were assessed. PATIENTS AND METHODS: Between January 1979 and April 2004, 88 patients who had received curative LDR brachytherapy (28 with postoperative close or positive margins, six with postoperative recurrence, six with recurrence after external-beam irradiation, and 48 with recurrent/residual cancer after curative brachytherapy) were analyzed retrospectively. Late complications were assessed based on the RTOG/EORTC late radiation morbidity score scheme. RESULTS: The 5-year relapse-free and cause-specific survival rates were 92% and 96%, respectively, in the close/positive margin group and 52% and 56%, respectively, in the postbrachytherapy recurrence or residual cancer group. The incidence of late side effects was 8% (2/26) in the close or positive margin group and 22% (4/18) in the postbrachytherapy group. The only grade 4 late complication (bone exposure) was observed in one patient in the postbrachytherapy group. CONCLUSION: LDR brachytherapy as reirradiation for recurrent/residual tongue cancer was effective, and there was no increase in complications.
PURPOSE: The efficacy of curative low-dose-rate (LDR) brachytherapy for recurrent and/or residual cancer following radical operation or irradiation and posttreatment quality of life (QoL) were assessed. PATIENTS AND METHODS: Between January 1979 and April 2004, 88 patients who had received curative LDR brachytherapy (28 with postoperative close or positive margins, six with postoperative recurrence, six with recurrence after external-beam irradiation, and 48 with recurrent/residual cancer after curative brachytherapy) were analyzed retrospectively. Late complications were assessed based on the RTOG/EORTC late radiation morbidity score scheme. RESULTS: The 5-year relapse-free and cause-specific survival rates were 92% and 96%, respectively, in the close/positive margin group and 52% and 56%, respectively, in the postbrachytherapy recurrence or residual cancer group. The incidence of late side effects was 8% (2/26) in the close or positive margin group and 22% (4/18) in the postbrachytherapy group. The only grade 4 late complication (bone exposure) was observed in one patient in the postbrachytherapy group. CONCLUSION: LDR brachytherapy as reirradiation for recurrent/residual tongue cancer was effective, and there was no increase in complications.
Authors: Faycal El Majdoub; Anna Brunn; Frank Berthold; Volker Sturm; Mohammad Maarouf Journal: Strahlenther Onkol Date: 2009-02-25 Impact factor: 3.621
Authors: Iraklis Vastardis; Bojan Pajic; Richard H Greiner; Brigitte Pajic-Eggspuehler; Daniel M Aebersold Journal: Strahlenther Onkol Date: 2009-12 Impact factor: 3.621
Authors: Zoltán Takácsi-Nagy; Györgyi Muraközy; Péter Pogány; János Fodor; Zsolt Orosz Journal: Strahlenther Onkol Date: 2009-03-28 Impact factor: 3.621
Authors: Y Ozaki; H Watanabe; A Kaida; M Miura; K Nakagawa; K Toda; R Yoshimura; Y Sumi; T Kurabayashi Journal: J Radiat Res Date: 2017-07-01 Impact factor: 2.724
Authors: Rafael Trindade Tatit; Paulo Eduardo Albuquerque Zito Raffa; Giovana Cassia de Almeida Motta; André Alexandre Bocchi; Júlia Loripe Guimaraes; Paulo Roberto Franceschini; Paulo Henrique Pires de Aguiar Journal: Surg Neurol Int Date: 2021-06-21